Detalhe da pesquisa
1.
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B).
J Hepatol
; 64(5): 1011-1019, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26739688
2.
Follow-up of patients with chronic hepatitis C and a sustained viral response.
Liver Int
; 36 Suppl 1: 67-71, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26725900
3.
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Gut
; 64(6): 948-56, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25080450
4.
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
J Hepatol
; 63(1): 30-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25703086
5.
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Liver Int
; 35 Suppl 1: 18-20, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25529083
6.
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
J Hepatol
; 60(3): 490-9, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24444658
7.
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
Antimicrob Agents Chemother
; 58(9): 5332-41, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24982076
8.
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
Hepatology
; 58(6): 1897-906, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382638
9.
Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?
Liver Int
; 34 Suppl 1: 11-2, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24373072
10.
Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
J Hepatol
; 58(2): 391-4, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23063419
11.
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
J Hepatol
; 59(1): 11-7, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23439259
12.
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Gut
; 61(10): 1473-80, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22387529
13.
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
Gastroenterology
; 140(2): 459-468.e1; quiz e14, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21034744
14.
Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
Liver Int
; 32 Suppl 1: 61-3, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22212574
15.
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.
Liver Int
; 32(10): 1477-92, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22891751
16.
Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
J Hepatol
; 55(6): 1187-94, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21703195
17.
Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy?
Hepatology
; 58(2): 828, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23315935
18.
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Lancet Gastroenterol Hepatol
; 2(3): 177-188, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28404133
19.
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
World J Gastroenterol
; 21(18): 5647-53, 2015 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25987791
20.
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Clin Res Hepatol Gastroenterol
; 39(4): 443-50, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25636238